Beyond Catalog Numbers: How We Validate Every Antibody Lot
The Reproducibility Crisis in Antibody-Based Research
A series of high-profile analyses have quantified the scope of the antibody reproducibility problem:
- Bhatt et al. estimated that $800 million per year is wasted on poorly performing antibodies in the US alone (F1000Research, 2015)
- Berglund et al. (Human Protein Atlas) tested 5,436 commercial antibodies and found that only ~50% were suitable for at least one standard application (IHC, ICC, WB) (Molecular & Cellular Proteomics, 2008)
- A Nature survey of 1,500 researchers revealed that 36% had spent >1 month troubleshooting antibody problems that ultimately traced to reagent quality (Nature, 2015)
Root Causes of Antibody Failure
1. Lot-to-Lot Variability (Polyclonal Antibodies)
Polyclonal antibodies are derived from animal serum — each bleed represents a different snapshot of the animal's humoral immune response. Epitope dominance, antibody titers, and cross-reactivity profiles shift between bleeds. Without lot-specific validation, researchers are essentially using a different reagent each time they reorder.
2. Insufficient Specificity Testing
Many vendors validate antibodies against the immunogen peptide (ELISA) but not against the full-length endogenous protein in cellular context. An antibody that binds a linear epitope in ELISA may fail to recognize the native protein in WB (denatured) or vice versa. The gold standard for specificity testing includes:
- Knockout/knockdown controls — WB/IF in cell lines with genetic deletion or siRNA knockdown of the target
- Recombinant overexpression — positive control with transfected target protein
- Multi-cell line panel — testing against lysates from cells known to express/not express the target
3. Application-Specific Performance
Antibody performance is application-dependent. An antibody validated for WB (denatured epitope) may fail in IP (native conformation) or IHC (fixed tissue). Performance must be validated for each intended application.
Our Multi-Method Validation Pipeline
| Step | Method | Purpose | Acceptance Criteria |
|---|---|---|---|
| 1 | SDS-PAGE (reducing + non-reducing) | Purity, molecular weight, heavy/light chain ratio | >90% purity, correct MW bands |
| 2 | Direct ELISA (antigen titration) | Binding affinity, titer determination | EC₅₀ within 2-fold of reference lot |
| 3 | Western Blot (cell lysate panel) | Specificity, cross-reactivity screen | Single band at predicted MW, no significant off-targets |
| 4 | Flow Cytometry (select clones) | Cell surface marker recognition | Clear positive/negative separation (SI > 5) |
Data Transparency
Every antibody shipment includes a lot-specific Certificate of Analysis containing:
- Actual SDS-PAGE gel image (not a representative image from a different lot)
- ELISA binding curve with calculated titer
- Western blot image with molecular weight markers and cell line identification
- Recommended working dilutions derived from the specific lot's titration data
We believe that data transparency is the foundation of research reproducibility. If an antibody lot does not meet our QC criteria, it is not released — regardless of production cost.
References
- Bhatt, D. et al. “The antibody/reagent problem and challenges in reproducibility.” F1000Research 4, 672 (2015)
- Berglund, L. et al. “A genecentric Human Protein Atlas for expression profiles.” Molecular & Cellular Proteomics 7, 2019–2027 (2008)
- Baker, M. “Reproducibility crisis: blame it on the antibodies.” Nature 521, 274–276 (2015)
- Uhlen, M. et al. “A proposal for validation of antibodies.” Nature Methods 13, 823–827 (2016)
Leave a Reply